Celera to Webcast Its Analyst and Investor Meeting on September 9, 2008

Celera Corporation (NASDAQ:CRA), announced today that it will webcast its Analyst & Investor Meeting in New York, NY, on Tuesday, September 9, 2008. The live webcast is scheduled to begin at 8:30 a.m. Eastern Time. At the meeting, Celera's senior management will discuss the strategy for the business following the recent separation of Celera from Applied Biosystems, and update the investment community on the status of key services and products and development programs. Celera management will also present its strategy for growth across all parts of the business.

Separately, Celera will also webcast its presentations at two upcoming financial conferences in September. Celera will webcast its presentation at the Thomas Weisel Partners Healthcare conference on Friday, September 5, 2008. The live webcast is scheduled to begin at 9:10 am ET. Joel Jung, Chief Financial Officer at Celera, and David Speechly, Ph.D., Vice President of Corporate Affairs at Celera, will provide a brief overview of Celera’s business, followed by a question and answer session with investors and a Thomas Weisel Partners financial analyst.

Celera will also webcast its presentation at the UBS Global Life Sciences Conference on Monday, September 22. The live webcast is scheduled to begin at 2:30 pm ET when Kathy Ordoñez, President of Celera, will provide an overview of the business and its strategy for growth.

Interested parties may access the live webcast and replay by visiting the Investors & Media section of either the Celera website at www.celera.com or the Applera website at www.applera.com. It is suggested that participants access the webcast 15 minutes before the start of the live broadcast. The webcast replay will be archived on the Presentations page of the Investors & Media section of each website.

About Celera

Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.

Copyright© 2008. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.